<VariationArchive VariationID="1411219" VariationName="NM_000168.6(GLI3):c.3956dup (p.Gln1320fs)" VariationType="Duplication" Accession="VCV001411219" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-02-28" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1343609" VariationID="1411219">
      <GeneList>
        <Gene Symbol="GLI3" FullName="GLI family zinc finger 3" GeneID="2737" HGNC_ID="HGNC:4319" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>7p14.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="41960949" stop="42264268" display_start="41960949" display_stop="42264268" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="42000546" stop="42276617" display_start="42000546" display_stop="42276617" Strand="-" />
          </Location>
          <OMIM>165240</OMIM>
          <Haploinsufficiency last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLI3">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-01-12" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=GLI3">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000168.6(GLI3):c.3956dup (p.Gln1320fs)</Name>
      <CanonicalSPDI>NC_000007.14:41965116:CCC:CCCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>7p14.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="7" Accession="NC_000007.14" start="41965116" stop="41965117" display_start="41965116" display_stop="41965117" variantLength="1" positionVCF="41965116" referenceAlleleVCF="T" alternateAlleleVCF="TC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="7" Accession="NC_000007.13" start="42004714" stop="42004715" display_start="42004714" display_stop="42004715" variantLength="1" positionVCF="42004714" referenceAlleleVCF="T" alternateAlleleVCF="TC" />
      </Location>
      <ProteinChange>Q1320fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.13" sequenceAccession="NC_000007" sequenceVersion="13" change="g.42004717dup" Assembly="GRCh37">
            <Expression>NC_000007.13:g.42004717dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000007.14" sequenceAccession="NC_000007" sequenceVersion="14" change="g.41965119dup" Assembly="GRCh38">
            <Expression>NC_000007.14:g.41965119dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008434.1" sequenceAccession="NG_008434" sequenceVersion="1" change="g.276904dup">
            <Expression>NG_008434.1:g.276904dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000168.6" sequenceAccession="NM_000168" sequenceVersion="6" change="c.3956dup" MANESelect="true">
            <Expression>NM_000168.6:c.3956dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000159.3" sequenceAccession="NP_000159" sequenceVersion="3" change="p.Gln1320fs">
            <Expression>NP_000159.3:p.Gln1320fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2128705204" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000168.6(GLI3):c.3956dup (p.Gln1320fs) AND multiple conditions" Accession="RCV001918776" Version="3">
        <ClassifiedConditionList TraitSetID="11675">
          <ClassifiedCondition DB="MedGen" ID="C0265306">Greig cephalopolysyndactyly syndrome</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0265220">Pallister-Hall syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-12-06" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-12-06" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">24736735</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="11675" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2006" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Greig cephalopolysyndactyly syndrome</ElementValue>
                <XRef ID="Greig+Cephalopolysyndactyly+Syndrome/3182" DB="Genetic Alliance" />
                <XRef ID="MONDO:0008287" DB="MONDO" />
                <XRef ID="32985001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Greig syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Polysyndactyly with peculiar skull shape</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">GCPS</ElementValue>
                <XRef Type="MIM" ID="175700" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Typical Greig cephalopolysyndactyly syndrome (GCPS) is characterized by macrocephaly, widely spaced eyes associated with increased interpupillary distance, preaxial polydactyly with or without postaxial polydactyly, and cutaneous syndactyly. Developmental delay, intellectual disability, or seizures appear to be uncommon manifestations (~&lt;10%) of GCPS and may be more common in individuals with large (&gt;300-kb) deletions that encompass GLI3. Approximately 20% of individuals with GCPS have hypoplasia or agenesis of the corpus callosum.</Attribute>
                <XRef ID="NBK1446" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="6550" />
                <XRef ID="6550" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301619</ID>
                <ID Source="BookShelf">NBK1446</ID>
              </Citation>
              <XRef ID="380" DB="Orphanet" />
              <XRef ID="C0265306" DB="MedGen" />
              <XRef ID="MONDO:0008287" DB="MONDO" />
              <XRef Type="MIM" ID="175700" DB="OMIM" />
            </Trait>
            <Trait ID="3351" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Pallister-Hall syndrome</ElementValue>
                <XRef ID="Pallister-Hall+syndrome/5543" DB="Genetic Alliance" />
                <XRef ID="MONDO:0007804" DB="MONDO" />
                <XRef ID="56677004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hypothalamic hamartoblastoma, hypopituitarism, imperforate anus, and postaxial polydactyly</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PHS1</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PHS</ElementValue>
                <XRef Type="MIM" ID="146510" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">GLI3-related Pallister-Hall syndrome (GLI3-PHS) is characterized by a spectrum of anomalies ranging from polydactyly, asymptomatic bifid epiglottis, and hypothalamic hamartoma at the mild end to laryngotracheal cleft with neonatal lethality at the severe end. Individuals with mild GLI3-PHS may be incorrectly diagnosed as having isolated postaxial polydactyly type A. Individuals with GLI3-PHS can have pituitary insufficiency and may die as neonates from undiagnosed and untreated adrenal insufficiency.</Attribute>
                <XRef ID="NBK1465" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7305" />
                <XRef ID="7305" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301638</ID>
                <ID Source="BookShelf">NBK1465</ID>
              </Citation>
              <XRef ID="672" DB="Orphanet" />
              <XRef ID="C0265220" DB="MedGen" />
              <XRef ID="MONDO:0007804" DB="MONDO" />
              <XRef Type="MIM" ID="146510" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4195889" SubmissionDate="2024-02-15" DateLastUpdated="2024-02-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="15343919|MedGen:C0265220;C0265306" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002186291" DateUpdated="2024-02-28" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-12-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24736735</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Gln1320Thrfs*30) in the GLI3 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 261 amino acid(s) of the GLI3 protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the GLI3 protein in which other variant(s) (p. Thr1488Lysfs*23) have been determined to be pathogenic (PMID: 24736735). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with GLI3-related conditions. This variant is not present in population databases (gnomAD no frequency).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GLI3" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000007.13:g.42004714_42004715insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease" multipleConditionExplanation="Uncertain">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0265220" Type="CUI" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0265306" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12507860</SubmissionName>
          <SubmissionName>SUB14224806</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4195889" TraitType="Disease" MappingType="XRef" MappingValue="C0265220" MappingRef="MedGen">
        <MedGen CUI="C0265220" Name="Pallister-Hall syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4195889" TraitType="Disease" MappingType="XRef" MappingValue="C0265306" MappingRef="MedGen">
        <MedGen CUI="C0265306" Name="Greig cephalopolysyndactyly syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

